A murine model of neurofibromatosis type 2 that accurately phenocopies human schwannoma formation

被引:65
|
作者
Gehlhausen, Jeffrey R. [1 ,2 ]
Park, Su-Jung [1 ,2 ]
Hickox, Ann E. [7 ,8 ]
Shew, Matthew [1 ]
Staser, Karl [1 ,2 ]
Rhodes, Steven D. [1 ,3 ]
Menon, Keshav [1 ]
Lajiness, Jacquelyn D. [1 ,2 ]
Mwanthi, Muithi [1 ,4 ]
Yang, Xianlin [1 ]
Yuan, Jin [1 ]
Territo, Paul [5 ]
Hutchins, Gary [5 ]
Nalepa, Grzegorz [1 ,2 ]
Yang, Feng-Chun [1 ,3 ]
Conway, Simon J. [1 ,2 ,3 ]
Heinz, Michael G. [7 ,8 ]
Stemmer-Rachamimov, Anat [9 ,10 ]
Yates, Charles W. [6 ]
Clapp, D. Wade [1 ,2 ,4 ]
机构
[1] Indiana Univ Sch Med, Herman B Wells Ctr Pediat Res, Dept Pediat, Indianapolis, IN 46202 USA
[2] Indiana Univ Sch Med, Dept Biochem, Indianapolis, IN 46202 USA
[3] Indiana Univ Sch Med, Dept Anat & Cell Biol, Indianapolis, IN 46202 USA
[4] Indiana Univ Sch Med, Dept Microbiol & Immunol, Indianapolis, IN 46202 USA
[5] Indiana Univ Sch Med, Dept Radiol, Indianapolis, IN 46202 USA
[6] Indiana Univ Sch Med, Dept Otolaryngol, Indianapolis, IN 46202 USA
[7] Purdue Univ, Dept Biomed Engn, W Lafayette, IN 47907 USA
[8] Purdue Univ, Dept Speech Language & Hearing Sci, W Lafayette, IN 47907 USA
[9] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA
[10] Harvard Univ, Sch Med, Boston, MA USA
关键词
NERVE SHEATH TUMORS; VESTIBULAR SCHWANNOMA; MOUSE MODELS; HEARING-LOSS; CELLS; MICE; ORIGIN; NF1;
D O I
10.1093/hmg/ddu414
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Neurofibromatosis type 2 (NF2) is an autosomal dominant genetic disorder resulting from germline mutations in the NF2 gene. Bilateral vestibular schwannomas, tumors on cranial nerve VIII, are pathognomonic for NF2 disease. Furthermore, schwannomas also commonly develop in other cranial nerves, dorsal root ganglia and peripheral nerves. These tumors are a major cause of morbidity and mortality, and medical therapies to treat them are limited. Animal models that accurately recapitulate the full anatomical spectrum of human NF2-related schwannomas, including the characteristic functional deficits in hearing and balance associated with cranial nerve VIII tumors, would allow systematic evaluation of experimental therapeutics prior to clinical use. Here, we present a genetically engineered NF2 mouse model generated through excision of the Nf2 gene driven by Cre expression under control of a tissue-restricted 3.9kbPeriostin promoter element. By 10 months of age, 100% of Postn-Cre; Nf2(flox/flox) mice develop spinal, peripheral and cranial nerve tumors histologically identical to human schwannomas. In addition, the development of cranial nerve VIII tumors correlates with functional impairments in hearing and balance, as measured by auditory brainstem response and vestibular testing. Overall, the Postn-Cre; Nf2(flox/flox) tumor model provides a novel tool for future mechanistic and therapeutic studies of NF2-associated schwannomas.
引用
收藏
页码:1 / 8
页数:8
相关论文
共 50 条
  • [1] Chemopreventative celecoxib fails to prevent schwannoma formation or sensorineural hearing loss in genetically engineered murine model of neurofibromatosis type 2
    Wahle, Benjamin M.
    Hawley, Eric T.
    He, Yongzheng
    Smith, Abbi E.
    Yuan, Jin
    Masters, Andi R.
    Jones, David R.
    Gehlhausen, Jeffrey R.
    Park, Su-Jung
    Conway, Simon J.
    Clapp, D. Wade
    Yates, Charles W.
    ONCOTARGET, 2018, 9 (01) : 718 - 725
  • [2] New developments in neurofibromatosis type 2 and vestibular schwannoma
    Ren, Yin
    Chari, Divya A.
    Vasilijic, Sasa
    Welling, D. Bradley
    Stankovic, Konstantina M.
    NEURO-ONCOLOGY ADVANCES, 2021, 3 (01)
  • [3] Gene replacement therapy in a schwannoma mouse model of neurofibromatosis type 2
    Prabhakar, Shilpa
    Beauchamp, Roberta L.
    Cheah, Pike See
    Yoshinaga, Akiko
    Abou Haidar, Edwina
    Lule, Sevda
    Mani, Gayathri
    Maalouf, Katia
    Stemmer-Rachamimov, Anat
    Jung, David H.
    Welling, Bradley
    Giovannini, Marco
    Plotkin, Scott R.
    Maguire, Casey A.
    Ramesh, Vijaya
    Breakefield, Xandra O.
    MOLECULAR THERAPY METHODS & CLINICAL DEVELOPMENT, 2022, 26 : 169 - 180
  • [4] NEUROFIBROMATOSIS TYPE-2 WITHOUT VESTIBULAR SCHWANNOMA
    MAUTNER, VF
    LINDENAU, M
    KOPPEN, J
    HAZIM, W
    KLUWE, L
    ZENTRALBLATT FUR NEUROCHIRURGIE, 1995, 56 (02): : 83 - 87
  • [5] Management Strategy of Vestibular Schwannoma in Neurofibromatosis Type 2
    Odat, Haitham Ahmad
    Piccirillo, Enrico
    Sequino, Giuliano
    Taibah, Abdelkader
    Sanna, Mario
    OTOLOGY & NEUROTOLOGY, 2011, 32 (07) : 1163 - 1170
  • [6] Bilateral Spontaneous Regression of Vestibular Schwannoma in Neurofibromatosis Type 2
    Sebok, Martina
    van Niftrik, Christiaan Hendrik Bas
    Bozinov, Oliver
    WORLD NEUROSURGERY, 2018, 113 : 195 - 197
  • [7] A Bilateral Vestibular Schwannoma is Not Always Related to Neurofibromatosis Type 2
    Abeshi, Andi
    Ferri, Gian Gaetano
    JOURNAL OF INTERNATIONAL ADVANCED OTOLOGY, 2023, 19 (03) : 263 - 265
  • [8] Outcome of translabyrinthine surgery for vestibular schwannoma in neurofibromatosis type 2
    Moffat, D. A.
    Lloyd, S. K. W.
    Macfarlane, R.
    Mannion, R.
    King, A.
    Rutherford, S.
    Axon, P. R.
    Donnelly, N.
    Freeman, S.
    Tysome, J. R.
    Evans, D. G.
    Ramsden, R. T.
    BRITISH JOURNAL OF NEUROSURGERY, 2013, 27 (04) : 446 - 453
  • [9] Predictors of vestibular schwannoma growth in patients with neurofibromatosis Type 2
    Baser, ME
    Makariou, EV
    Parry, DM
    JOURNAL OF NEUROSURGERY, 2002, 96 (02) : 217 - 222
  • [10] Factors predicting growth of vestibular schwannoma in neurofibromatosis type 2
    Ito, Eiji
    Saito, Kiyoshi
    Yatsuya, Hiroshi
    Nagatani, Tetsuya
    Otsuka, Goro
    NEUROSURGICAL REVIEW, 2009, 32 (04) : 425 - 432